Introduction
Acute promyelocytic leukemia (APL), characterized by its distinctive FAB-M3 morphology and its association with a bleeding coagulopathy, is now known to be associated with at least four types of non-random reciprocal chromosomal translocation but always involving the retinoic acid receptor alpha gene (RAR␣) on chromosome 17. The majority of APL patients carry chromosomal translocation t (15;17) that fuses RAR␣ to the promyelocytic leukemia gene (PML) encoding a member of the RING finger family of proteins, on chromosome 15 band q22. [1] [2] [3] There are also cases of APL involving the fusion of RAR␣ to three different partner genes, ie (1) promyelocytic leukemia zinc finger gene (PLZF), which encodes a transcriptional repressor that shares an N-terminal POZ motif and a C-terminal DNA binding domain of Krü ppel-like C2-H2 zinc fingers, on chromosome 11 band q23; 4 (2) nucleophosmin gene (NPM) which codes for a nucleolar phosphoprotein possibly involved in ribosome processing or assembly, on chromosome 5 band q35; 5 and (3) nuclear mitotic apparatus gene, NuMA, on chromosome 11 band q13. 6 Although these APL-associated fusion proteins are structurally different, they all share an identical portion of RAR␣ that includes the DNA, ligand, co-repressor and co-activator binding domains fused to the partner gene ( Figure 1 ).
RAR␣s are members of a superfamily of nuclear hormone receptors, which affect many physiological processes including differentiation and growth arrest of various cell types [7] [8] [9] including hematopoietic cells. 10 RARs can dimerize with retinoid X receptors (RXRs) to bind to retinoic acid response elements (RAREs) located in promoter/enhancer regions of specific genes. In the absence of ligand (RA), RAR/RXR heterodimers will associate with transcriptional co-repressors (SMRT/N-CoR), [11] [12] [13] which recruit transcriptional repressors, Sin3 [14] [15] [16] and histone deacetylase. 17 This renders the nearby chromatin inaccessible to transcriptional activators (SRC-1, RIP-140), and result in repression of basal transcription. ATRA can induce dissociation of the co-repressor complex followed by recruitment of co-activators to the transcriptional complex thus resulting in the activation of gene expression. [11] [12] [13] It has been shown that both PML-RAR␣ 18 and PLZF-RAR␣ 19, 20 can bind to retinoic acid response elements (RAREs) as homodimers or heterodimers with RXR. Thus these APL fusion proteins which mimic wild-type RAR␣ can be considered as RAR mutants.
The majority of APL patients with PML-RAR␣ fusion 21 and the rare cases of NPM-RAR␣ fusion 22 respond to RA-induced differentiation therapy; however APL patients with PLZF-RAR␣ fusion is unresponsive. 23 These findings suggest that the fusion partners to RAR␣ may influence the response of ATRA therapy. Recent studies have shown that ATRA by inducing the dissociation of the transcriptional co-repressors, SMRT [24] [25] [26] /NCoR, 27, 28 from PML-RAR␣ but not the PLZF-RAR␣, can release suppression by Sin3 and histone deacetylase from the transcriptional complex, and allow the cells to differentiate. In contrast, the resistance of PLZF-RAR␣ to ATRA therapy may be explained by the strong associations between N-CoR/SMRT and the N-terminus region 27 /POZ domain 24 of the wild-type PLZF that was retained in the PLZF-RAR␣ fusion. In addition PLZF has also been found to directly interact with Sin3 and histone deacetylase resulting in gene repression. 25, 28, 29 To determine whether SMRT/N-CoR mediated co-repression is a general mechanism for all APL-associated fusion proteins, in this study, we investigate and compare the binding affinities of the wild-type RAR␣, PML-, PLZF-and NPM-RAR␣ fusion proteins to RAREs, transcriptional co-repressor, SMRT, and transcriptional co-activator, RIP-140. 30, 31 We show that NPM-RAR␣, which is sensitive to RA induction, also associates with SMRT, and this interaction, like those with PML-RAR␣, can be abrogated by ATRA. Our results also demonstrate that binding of PML-, PLZF-and NPM-RAR␣ to RIP-140 can be enhanced by ATRA but with a lower sensitivity compared to the wild-type RAR␣. 
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Materials and methods
Expression plasmids and glutathione-S-transferase (GST) fusion proteins
Constructions of PML-RAR␣, PLZF-RAR␣, RAR␣ and RXR␣ in pSG5 plasmids were carried out as previously described. 20 Long type of NPM-RAR␣ 5 was constructed in pSG5 vector by PCR on both NPM and RAR␣, with primers containing fusion region sequences and an introduced restriction site (RcaI, TCATGA) which keeps the amino acid sequence. A schematic diagram indicating the structure of constructs used in the study is shown in Figure 1 . GST-C-SMRT plasmid (from 981aa to the C-terminal stop) 12 was a kind gift from RM Evans (Salk Institute, San Diego, CA, USA). The GST RIP-140 fusion construct (HpaI-HpaI cDNA fragment) which includes the receptor interaction domain 32 was a kind gift from JP Capone (McMaster University, Canada). All GST fusion proteins were prepared using standard protocols.
Gel shift DNA binding assay
In vitro synthesized proteins were made using coupled transcription-translation system according to the manufacturer's manual (Promega, Madison, WI, USA). The amounts of protein synthesized were assessed using TCA precipitation and incorporation count on parallel in vitro translation assays in the presence of 35 
S-methionine.
Binding affinity studies to RAREs:
In each reaction, an equal amount of in vitro translated proteins was pre-incubated for 15 min at room temperature in buffer B (20 mM Hepes, pH 7.4; 50 mM KCl; 1 mM ␤-mercaptoethanol; 10% glycerol; 1 g of poly(dI-dC) (Amersham Pharmacia Biotech, UK; 100 g bovine serum albumin (BSA)). Then 32 P-ATP probe (100 000 c.p.m. per assay corresponding to ෂ15 fmol of probe) representing each of the 10 RAREs (DR1G-5G and DR1T-5T) 18 ( Figure 2a ) was then added to the reaction for further 30-min incubations at room temperature and 4°C, respectively. Protein-DNA complexes were resolved in 6% polyacylamide gels equilibrated with 0.5 × TBE and run at 250 V. The gels were fixed in 10% acetic acid/30% methanol for 15 min, dried and autoradiographed at −80°C.
Binding affinity studies to SMRT (only DR5G element was used):
In each reaction, an equal amount of in vitro translated proteins was pre-incubated under conditions as described above. Then 15 fmol 32 P-labeled DR5G probe was added together with or without (1) GST-C-SMRT fusion protein (0.3, 0.9, 1.5, 2.1 g, respectively) and (2) all-trans retinoic acid (final concentration at 10 −8 , 10 −7 , 10 −6 , 10
respectively), and processed in a similar manner as described for RAREs binding assay.
In vitro interaction assays
35
S-methionine-labeled proteins were incubated with 5 g of GST or GST-RIP-140 fusion proteins conjugated glutathione sepharose (Amersham Pharmacia Biotech) in NETE buffer (20 mM Tris, pH 8.0; 100 mM NaCl; 1 mM EDTA; 0.5% NP-40) at 4°C for 90 min. Incubations were performed in the Leukemia absence or the presence of 10 −8 , 10 −7 , 10 −6 M ATRA (final concentration). The beads were then washed extensively five times with buffer H (20 mM Hepes, pH 7.7; 50 mM KCl, 20% glycerol; 0.1% NP-40). Bound proteins were eluted in loading buffer at 90°C, and separated in 10% SDS-PAGE. The gels were fixed, dried and autoradiographed at −80°C.
Results
Comparison of the DNA binding properties of homoand heterodimers of NPM-, PLZF-, PML-RAR␣ and with the wild-type RAR␣/RXR␣ heterodimer
It has been previously shown that PML-RAR␣ can form homodimers or heterodimers with RXR to bind to 10 different RAREs consisting of directly repeated 5Ј-PuGGTCA (DRnG elements) or 5Ј-PuGTTCA (DRnT elements) motifs separated by spacers of different length (n = 1-5 bp). 18 We set up similar gel shift DNA binding assays to compare the binding properties of NPM-, PLZF-and PML-RAR␣ fusion proteins, with the wildtype RAR␣/RXR␣ heterodimers. We showed that NPM-and PLZF-RAR␣, like PML-RAR␣, could form homodimers to bind to 10 different RAREs (Figure 2 ). In contrast with the wild-type RAR␣/RXR␣, several differences in response element preference, like those reported for PML-RAR␣, 18 were found. 
Differential binding of SMRT to wild-type RAR␣/RXR␣, NPM-, PML-or PLZF-RAR␣ homodimer
In the absence of ATRA, RARs will suppress transcription by recruiting transcriptional repressors including Sin3 and histone deacetylase through co-repressors such as SMRT/NCoR. [11] [12] [13] [14] [15] [16] [17] Using gel shift assays, we show that NPM-, PMLand PLZF-RAR homodimers would also associate with SMRT, but with different binding affinity as compared with the wildtype RAR/RXR heterodimer ( Figure 3) . A SMRT retardation band could be seen when 0.3 g GST-SMRT fusion protein was added to these APL fusion homodimers (Figure 3 , lane 12, 20 and 28). However the corresponding SMRT retardation bands of RAR/RXR could not be found until 0.9 g GST-SMRT fusion protein was added (Figure 3, lane 4) . This retardation
Figure 2
Binding of the wild-type RAR␣/RAR␣ and the APL-associated fusion proteins to RAREs (DRnG and DRnT). (a) Sequences of RARE probes used in the gel shift assays. (b) Binding of in vitro translated proteins to RARE probes. The total amount of protein used for each experiment was the same (Materials and methods). For heterodimer study, equal amounts of each dimerization partner was added to the reaction. Arrows indicate the non-specific binding due to the reticulocyte lysate. All track lanes come from the same autoradiogram and have been exposed for the same amount of time. The percentage of probe bound for each lane was calculated and shown as pentagram.
Figure 3
Gel shift assay on the interaction between GST-C-SMRT and the wild-type RAR␣/RXR␣ heterodimer or the APL-associated fusion proteins (PML-, PLZF-, and NPM-RAR␣) homodimers on DR5G element, and the effect of ATRA. Amount of GST-SMRT fusion protein and ATRA used were showed. Arrows indicate the SMRT retardation bands. band could not be seen using GST protein alone (data not shown). Upon ATRA treatment, the binding of SMRT to RAR/RXR was dissociated at low concentration of ATRA and no SMRT retardation band was seen at 10 −8 M ATRA (Figure 3,  lane 7) . In contrast, a much higher concentration of ATRA was required to dissociated SMRT from the APL fusion proteins, ie 10 −7 M ATRA for the loss of the SMRT retardation band for NPM-RAR␣ and PML-RAR␣ (Figure 3, lanes 17 and 25) , and 10 −6 -10 −5 M ATRA for PLZF-RAR␣ (Figure 3, lanes 34 and 35) .
Compared to the wild-type RAR␣, interaction between the transcriptional co-activator, RIP-140, and PML-, NPM-or PLZF-RAR␣ is less sensitive to ATRA
Gene expression requires dissociation of transcriptional corepressors/repressors and recruitment of co-activator/activator to the transcriptional complex. After showing the interaction between the APL-associated fusion proteins and the transcriptional co-repressor, SMRT, we compared the in vitro binding properties between these APL-associated fusion proteins and the wild-type RAR␣ to a potential transcriptional co-activator, RIP-140, in response to ATRA. By GST pulldown, both the wild-type RAR␣ and the APL-associated fusion proteins could interact with RIP-140 even in the absence of ligand (Figure 4a ). However, in the presence of ATRA, the interaction between the wild-type RAR␣ and RIP-140 is greatly enhanced, ie by more than four-fold at 10 −8 M ATRA and more than 10-fold at 10 −6 M ATRA (Figure 4a and b) . This result suggests that RIP-140 is a transcriptional co-activator for RAR␣. [32] [33] [34] The interactions between the APL-associated fusion proteins and RIP-140 were also stimulated by ATRA but to a lesser extent, ie the interactions between the APL-associated fusion proteins and RIP-140 were increased by less than five-fold at 10 
Discussion
In this study, we have compared the binding affinities of three APL-associated fusion proteins, PML-, PLZF-and NPM-RAR␣ towards RAREs, the transcriptional co-repressor, SMRT and the co-activator, RIP-40 in order to better understand the molecular basis of retinoic acid responses in APL.
It has been previously reported that PML-RAR␣ and PLZF- Leukemia RAR␣ can form homodimers via the coiled coil region of PML 18, 35 and the POZ domain of PLZF respectively. 20 We showed that NPM-RAR␣ could also form homodimers, probably through the N-terminal oligomerization domain of NPM that is essential to mediate oligomerization. 36, 37 The transformation ability of NPM-ALK fusion in non-Hodgkin's lymphoma requires the activation of its kinase activity as a result of oligomerization mediated by the NPM segment. 37 Whilst PML-, PLZF-and NPM-RAR␣ homodimers displayed similar binding patterns to RAREs, they were different from that of the wild-type RAR␣/RXR␣ (Figure 2b ). This consistently suggests that altered binding activities of APL-associated fusion proteins toward RAREs of the target genes may deregulate the gene expression that are tightly regulated by nuclear hormone receptor family. 18, 38, 39 Formation of RXR heterodimers is essential for RAR, TR, VDR and PPAR to have efficient binding to their response elements. 8, 40, 41 Our data show that NPM-RAR␣, like PML-and PLZF-RAR␣, can dimerize with RXR␣ to form heterodimers that bind to RAREs. This may affect the normal nuclear hormone receptor signaling pathways in at least two ways, ie by competing with wild-type RAR␣/RXR␣ for binding to RAREs in target genes thus affecting the expression of target genes which are normally regulated by RAR/RXR; and/or through the sequestration of RXR␣ and interfere with its functions. 18, 19 Our in vitro data show that SMRT-mediated suppression is a common pathway shared by PML-, PLZF-and NPM-RAR␣, ie (1) NPM-, PML-and PLZF-RAR␣, are bound to the transcriptional co-repressor, SMRT, in the absence of ATRA; and (2) the association between NPM-RAR␣ and SMRT, like that of PML-RAR␣, can be released by ATRA. SMRT can be dissociated from NPM-RAR␣ and PML-RAR␣ upon 10 −7 M ATRA whereas a higher level of ATRA (10 −6 to 10 −5 M) is required to displace SMRT from PLZF-RAR␣. The tight PLZF-RAR␣/SMRT association can be explained by a strong interaction between the POZ domain of PLZF and SMRT. 24 The dissociation of both PML-RAR␣ and NPM-RAR␣ from SMRT at pharmacological concentration of ATRA may partially underlie the biological basis for the response of APL patients with these fusion proteins.
Although previous studies [24] [25] [26] [27] [28] and our findings consistently show that APL-associated fusion proteins exhibit aberrant binding affinities to the transcriptional co-repressor, SMRT/NCoR, we are unaware of any studies on their interactions with transcriptional co-activators. RIP-140 originally identified as a hormone-dependent transcriptional co-activator for estrogen receptor, 30, 31 contains two consensus receptor-binding motifs, LXXLL that can interact with other nuclear receptors including TR␤, RAR␤ and RXR␣. 42 Our data show that the interactions between RIP-140 and PML-, PLZF-and NPM-RAR␣ are positively stimulated by ATRA although to a lesser extent compared to the wild-type RAR␣. At the pharmacological level of ATRA (10 −6 M), the binding affinities of PML-, PLZF-and NPM-RAR␣ to RIP-140, are increased (Figure 3 ) whilst simultaneously SMRT is dissociated from PML-RAR␣ and NPM-RAR␣ (Figure 4) but not from PLZF-RAR␣. We propose that the dissociation of SMRT by PML-RAR␣ and NPM-RAR␣ fusion proteins will lead to the expression of key target genes but not in the case of PLZF-RAR␣ where the strong association between PLZF-RAR␣ with co-repressors, SMRT/N-CoR, [24] [25] [26] [27] [28] and repressors, Sin3 and histone deacetylase, 25, 28, 29 will keep their target genes transcriptionally silent.
Our findings which show that PML-, PLZF-and NPM-RAR␣ fusion proteins have very similar binding profiles to RAREs, as well as association with common transcriptional co-repressor (SMRT) and co-activator (RIP-140), may help to explain why cells bearing these abnormal fusion genes share a similar APL phenotype. Although the in vitro binding affinity of three different APL-associated fusion proteins to RIP-140 is similar, it is unclear whether the lack of dissociation of SMRT is the only basis for the resistance to ATRA therapy seen in patients with PLZF-RAR␣. It will be useful to examine the role of other coactivators, eg SRC-1/CBP/TIF-2, to PML-, PLZF-and NPM-RAR␣, as well as to confirm the in vitro results by performing the binding studies in transfected myeloid leukaemic cells.
Finally, it is clear that APL-associated fusion proteins can influence several different signaling pathways in which the fusion partners of RAR␣ also play important roles. Through its coiled-coil domain to heterodimerize with PML, PML-RAR␣ is also believed to exert dominant negative inhibition on the wild-type PML, 43 which has recently been shown to be essential for Fas and caspase-dependent apoptosis 44 as well as a novel caspase independent apoptotic pathway. 45 The dominant negative effect of PML-RAR␣ on PML could render hematopoietic progenitor cells resistant to Fas-, TNF-and IFNinduced apoptosis. 44 Studies in these areas will facilitate new approaches in the treatment of de novo and relapsed APL cases that are resistant to ATRA therapy.
